Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047814 · ClinicalTrials.gov registry record · Phase 2
Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection
A Phase 2 study of Hepatitis C, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 9
- Study locations
NCT00047814: Completed Phase 2 study of Hepatitis C, sponsored by Astellas Pharma.
NCT00047814 is a Phase 2 study of Hepatitis C that has completed, run by Astellas Pharma. The registered enrollment target is 48 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047814, a Phase 2 study of Hepatitis C, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of 4 weeks therapy with FK788 in subjects with chronic hepatitis C virus (HCV) infection. Also, to assess the effect of FK788 on serum ALT concentration and hepatitis C viral level during therapy and for four weeks following therapy.
Conditions Studied
Interventions
- DRUG FK788
Study Locations (9)
North Carolina
- Carolinas Center for Liver Disease - Charlotte
- Duke University - Durham
California
- Liver Center Huntington Memorial Hospital - Pasadena
Colorado
- Rocky Mount Gastroenterology - Lakewood
Florida
- University of Florida and Shands Hospital - Gainsville
Massachusetts
- Liver Center BIDMC - Harvard - Boston
Missouri
- Gastroenterology and Hepatology - Kansas City
Pennsylvania
- Thomas Jefferson University, Gastroenterology and Hepatology - Philadelphia
Washington
- Northwest Medical Specialties, PLLC Infections Limited, P.S. - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
What the finished NCT00047814 record still lists
NCT00047814 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which FK788 is the first listed.
NCT00047814 lists 9 locations in 8 states (North Carolina, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT00047814 about?
NCT00047814 is a clinical study titled "Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection". The purpose of this study is to assess the safety, tolerability and pharmacokinetics of 4 weeks therapy with FK788 in subjects with chronic hepatitis C virus (HCV) infection. Also, to assess the effect of FK788 on serum ALT concentration and hepatitis C viral level during therapy and for four weeks ...
What is the current status of trial NCT00047814?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2002-10. Estimated completion is 2006-03.
What conditions does trial NCT00047814 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00047814?
The interventions under investigation include: FK788 (DRUG).
Who is sponsoring clinical trial NCT00047814?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00047814 being conducted?
This trial has 9 study locations across California, Colorado, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00047814's enrollment target sits among peer trials
48 75th of 106 higher than 32 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia